Participation in the study provided an opportunity for BRAF testing, which may have led investigators to preferentially enroll patients with characteristics indicative of BRAF V600E mutations, such as right-sided colon cancer or peritoneal dissemination. This evidence concerns the gene BRAF and colonic neoplasm.